Alzheon researchers discover key Alzheimer's substance
Image | Courtesy of Google Maps
Alzheon headquarters in Framingham
Researchers at the Framingham pharmaceutical firm Alzheon have discovered a substance in the brain inhibiting the formation of molecules that helps form Alzheimer's disease.
Alzheon, a clinical-stage company, is searching for new medicines to help patients with Alzheimer's, a disease that affects 5.7 million Americans.
The study in which the discovery was included appeared in the most recent issue of the peer-reviewed publication CNS Drugs. The company announced the discovery Monday.
“We are excited to contribute to a better understanding of the pathogenic and therapeutic mechanisms in Alzheimer’s disease," Martin Tolar, the president and CEO of Alzheon said in a statement.
The discovery, he added, strongly support the company's therapeutic approach and commitment to confirm the effectiveness of one of its Alzheimer's-fighting products, called ALZ-801. The oral drug received fast-track approval from the Food and Drug Administration last October, but Alzheon did not say when the drug might hit the market.
Alzheon separately announced on Monday it has appointed a new vice chairman of its board of directors. Neil Flanzraich was an early investor in the company and served as its chief business officer and a consultant from February to May 2018. He is the lead independent director at Colorado restaurant chain Chipotle Mexican Grill, where he was an early investor.
WBJ Web Partners
Most Recent
Most Recent
0 Comments